PACS
Pacs Group, Inc. Health Care Services-Skilled Nursing Care Facilities Russell 3000
$47.81Close
$7.5BMarket cap
$10.58 – $49.6852-week range
Nov 3, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
- Near its high 4% below its 52-week high
- Earnings growing EPS +53% year on year
Cautions
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
up 0.4%
price change
1mo
up 15.1%
price change
12-month return
up 291%
market up 11% ·
its own up 273%
F-score
—
— Not assessed
Altman Z″
0.85
Elevated risk
P/E
39.1×
price / earnings
PEG
0.17
P/E / EPS growth
P/B
7.9×
price / book
Earnings yield
up 4.1%
EBIT / enterprise value
Cheaper than
49%
of the market · around average
Revenue growth
up 29%
year on year
EPS growth
up 53%
latest quarter · -138 pts
Sales growth
up 9%
latest quarter · -2 pts
ROE
up 23%
return on equity
Free cash margin
up 8%
$404.2M FCF
D/E
0.26
long-term debt / equity
Net debt / EBITDA
0.2×
Interest cover
—EBIT / interest
Trade setup
ATR%
3.8%
$1.82 a day · 2×ATR $44.18
RS
97 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.10
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+1% vs market2 sessions after results
Financials
- Net 4%
- Free cash 8%
- Cash
- Long-term debt
| FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $2.4B | $3.1B | $4.1B | $5.3B |
| Operating income | $229.4M | $207.8M | $123.1M | $309.6M |
| Net income | $150.5M | $112.9M | $55.8M | $191.5M |
| Net margin | 6% | 4% | 1% | 4% |
| Earnings per share | $1.17 | $0.88 | $0.38 | $1.22 |
| Free cash flow | $92.6M | $63.7M | $367.3M | $404.2M |
| Free cash margin | 4% | 2% | 9% | 8% |
| Cash | $58.3M | $73.4M | $157.7M | $197.0M |
| Long-term debt | — | $195.7M | $251.0M | $244.8M |
| Shareholders' equity | $68.7M | $96.1M | $709.6M | $946.8M |
| Shares outstanding | — | 128.72m | 155.18m | 156.62m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 19, 2025 | Annual ↗ | Dec 31, 2024 | 323d |
| Nov 19, 2025 | Quarterly ↗ | Sep 30, 2025 | 50d |
| Nov 19, 2025 | Quarterly ↗ | Sep 30, 2024 | 415d |
| Nov 19, 2025 | Quarterly ↗ | Jun 30, 2025 | 142d |
| Nov 19, 2025 | Quarterly ↗ | Mar 31, 2025 | 233d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 21, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 4, 2026 | Results ↗ |
| Jun 15, 2026 | Shareholder vote ↗ |
| May 11, 2026 | Results ↗ |
| Apr 27, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 5, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 26, 2026 | Results ↗ |
| Dec 23, 2025 | Shareholder vote ↗ |
| Dec 1, 2025 | Material agreement ↗ |
| Nov 19, 2025 | Results ↗ |
| Nov 6, 2025 | Other events ↗ |
| Sep 11, 2025 | Results ↗ |